Event Abstract Back to Event Chemogenetic suppression of spontaneous seizures in a rat model for temporal lobe epilepsy Marie-Gabrielle Goossens1*, Emma Christiaen2, Paul Boon1, Kristl Vonck1, Evelien Carrette1, Jana Desloovere1, Chris Van Den Haute3, Veerle Baekelandt3, Wytse J. Wadman1, Christian Vanhove2 and Robrecht Raedt1 1 Ghent University, Department of Head and Skin, Belgium 2 Medical Imaging and Signal Processing, Ghent University, Belgium 3 Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Belgium AIM The hippocampus is believed to play a crucial role in seizure generation in temporal lobe epilepsy (TLE), a common form of medication-resistant epilepsy. This preclinical study evaluated chemogenetics as a potential therapy for TLE. Using this approach, excitatory neurons of the epileptic hippocampus were selectively inhibited through ligand-based activation of an inhibitory Designer Receptor Exclusively Activated by Designer Drugs (DREADD). METHODS The intraperitoneal kainic acid rat model for TLE was used. Animals (n=6) were injected in right hippocampus with adeno-associated viral vector carrying CamKIIα-hM4Di-mCherry. Two weeks after injection, rats were bilaterally implanted with depth electrodes in the dentate gyrus and CA1 region of both hippocampi. Seizure frequency before and after activating DREADDs with subclinical doses of clozapine was determined using continuous video-EEG recordings. First, EEG was monitored during a baseline period of six days. Next, single injections of different clozapine doses (0.01, 0.1 or 1 mg/kg bodyweight/24h, s.c.) and vehicle were compared. For each dose, EEG was monitored during three days of treatment. Finally, one dose was selected to evaluate an improved dosing scheme in a randomized-blind trial. EEG was monitored during a baseline period of one days, followed by one day of treatment with clozapine (0.1mg/kg bodyweight/6h) or vehicle. In all experiments, seizure frequency during baseline recordings was used to normalize the data. RESULTS Clozapine-induced activation of DREADDs had a dose-dependent seizure suppressing effect. Clozapine doses of 0.01, 0.1 and 1 mg/kg resulted in a clear lag in average cumulative seizure frequency of about 2, 5 and 8 hours respectively. Repeated clozapine administration resulted in a strong suppression of epileptic seizures in all animals tested. During treatment, the average daily seizure frequency was reduced with 86%±7% (SEM). CONCLUSION Clozapine-mediated activation of hM4Di DREADDs in excitatory hippocampal neurons temporary suppresses spontaneous seizures in a rat model for TLE in a dose-dependent way. Repeated clozapine administration results in a sustained suppression of epileptic seizures. Keywords: Temporal Lobe Epilepsy, IPKA rat model, DREADD receptors, Clozapine, Chemogenetic manipulation, hM4Di receptors Conference: 13th National Congress of the Belgian Society for Neuroscience , Brussels, Belgium, 24 May - 24 May, 2019. Presentation Type: Poster presentation Topic: Behavioral/Systems Neuroscience Citation: Goossens M, Christiaen E, Boon P, Vonck K, Carrette E, Desloovere J, Van Den Haute C, Baekelandt V, Wadman WJ, Vanhove C and Raedt R (2019). Chemogenetic suppression of spontaneous seizures in a rat model for temporal lobe epilepsy. Front. Neurosci. Conference Abstract: 13th National Congress of the Belgian Society for Neuroscience . doi: 10.3389/conf.fnins.2019.96.00024 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 28 Apr 2019; Published Online: 27 Sep 2019. * Correspondence: Mx. Marie-Gabrielle Goossens, Ghent University, Department of Head and Skin, Ghent, Belgium, MarieGabrielle.Goossens@UGent.be Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Marie-Gabrielle Goossens Emma Christiaen Paul Boon Kristl Vonck Evelien Carrette Jana Desloovere Chris Van Den Haute Veerle Baekelandt Wytse J Wadman Christian Vanhove Robrecht Raedt Google Marie-Gabrielle Goossens Emma Christiaen Paul Boon Kristl Vonck Evelien Carrette Jana Desloovere Chris Van Den Haute Veerle Baekelandt Wytse J Wadman Christian Vanhove Robrecht Raedt Google Scholar Marie-Gabrielle Goossens Emma Christiaen Paul Boon Kristl Vonck Evelien Carrette Jana Desloovere Chris Van Den Haute Veerle Baekelandt Wytse J Wadman Christian Vanhove Robrecht Raedt PubMed Marie-Gabrielle Goossens Emma Christiaen Paul Boon Kristl Vonck Evelien Carrette Jana Desloovere Chris Van Den Haute Veerle Baekelandt Wytse J Wadman Christian Vanhove Robrecht Raedt Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.
Read full abstract